Modified Sendai virus vaccine and imaging vector

Patent metadata

Field	Value
Publication number	US-10329584-B2
Application number	US-201715445635-A
Country	US
Kind code	B2
Filing date	Feb 28, 2017
Priority date	Apr 28, 2011
Publication date	Jun 25, 2019
Grant date	Jun 25, 2019

Abstract

The present invention relates to a Sendai virus or recombinant Sendai virus vector. In particular the present invention provides methods, vectors, formulations, compositions, and kits for a modified Enders strain Sendai viral vector. An immunogenic vector can be used in any in vitro or in vivo system. Moreover, some embodiments include vectors for imaging virus growth, location and transmission.

First claim

The invention claimed is:

1. A composition comprising a recombinant Enders/Z chimera Sendai viral vector comprising a modified Enders strain Sendai virus L gene, wherein said modified Enders strain Sendai virus L gene comprises wild type Enders strain Sendai virus L gene that contains nucleic acid sequence encoding at least one amino acid substitution with a corresponding different amino acid from wild type Z strain Sendai virus L gene, said at least one amino acid substitution is selected from the group consisting of S to G at position 155, R to K at position 258, G to E at position 466, G to E at position 482, S to Rat position 581, Q to Rat position 71 7, T to I at position 800, R to K at position 852, and combinations thereof.

2. A method, comprising-administering the composition of claim 1 to one or more cells in vitro to produce an increased number of said recombinant Enders/Z chimera Sendai viral vector.

3. A kit comprising:
i) the composition of claim 1 ; and
ii) instructions for use to vaccinate against a targeted pathogen.

4. The composition of claim 1 , further comprising at least one other antigen or immunogen.

5. The composition of claim 1 , wherein said Enders/Z chimera Sendai viral vector comprises a modified Enders strain Sendai virus genome that contains a foreign gene or portion thereof inserted at an intergenic junction(s) selected from the group consisting of a N-P, a P-M, a M-F, a F-HN, a HN-L, and combinations thereof.

6. The composition of claim 5 , wherein said genome of said Enders/Z chimera Sendai viral vector comprises a foreign gene or portion thereof inserted at intergenic junction F-HN.

7. The composition of claim 1 , wherein said modified Enders strain Sendai virus L gene comprises substitution of at least a portion of said wild type Enders strain Sendai virus L gene with a corresponding at least a portion of said wild type Z strain Sendai virus L gene.

8. The composition of claim 1 , wherein said Enders/Z chimera Sendai viral vector comprises a modified Enders strain Sendai virus genome that comprises a reporter gene.

9. A method of immunizing a subject, comprising administering to a subject in vivo the composition of claim 5 to produce an immunized subject, wherein said administering is in an amount effective to elicit an immune response.

10. The method of claim 9 , wherein said Enders/Z chimera Sendai viral vector in said immunized subject exhibits a phenotype comprising one or more of rescue, attenuation, and immunogenicity.

11. The method of claim 9 , wherein said Enders/Z chimera Sendai viral vector in said immunized subject is attenuated compared to wild type Z strain Sendai virus, and maintains immunogenicity.

Assignees

• St Jude Childrens Res Hospital

Inventors

• Hurwitz Julia Lea
• Takimoto Toru
• Russell Charles John
• Portner Allen
• Slobod Karen

Classifications

• C12N2760/18821

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

• C07K14/005

  from viruses · CPC title

• C12N2760/18534

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/18843

  viral genome or elements thereof as genetic vector · CPC title

• C12N2760/18734

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title